Atif Tantawy, Alaa-eldin Barghash, Sahar Badr* and Rania Gomaa

Synthesis of new heterocyclic compounds containing benzimidazole moiety as inhibitors of breast cancer cell growth

Abstract: A series of new benzimidazole derivatives, namely 2-acylbenzimidazoles **2–9**, a dihydroquinoxaline **10**, a benzoxazine **11**, quinolines **13–15** and fused 1,2,4-triazines **17–24** were synthesized. Structure elucidation of the compounds was conducted using IR, ¹H NMR, ¹³C NMR, mass spectral data and elemental analysis. These products were evaluated for *in vitro* antitumor activity against MCF7 cell line (human breast cancer). Compounds **13–15** and **24** manifested significant antitumor activity.

Keywords: antitumor; benzimidazoles; benzoxazines; quinolines; quinoxalines; 1,2,4-triazines; synthesis.

Introduction

Cancer represents the largest cause of death worldwide [1]. Despite progress in the efficacy of surgical operations to remove tumors, treatment with chemotherapy is considered to be one of the most important approaches. A literature survey has revealed the importance of benzimidazoles as antitumor agents [2–12] including bendamustine, dovitinib, Hoechst 33342 and Hoechst 33258 (Figure 1). Recently, benzoxazines [13, 14] and quinoxalines [15, 16] have been identified as anticancer agents. Certain quinolines [17–20] and 1,2,4-triazines [21–23] are also active. Hence, the aim of the current study was the synthesis of novel benzimidazole derivatives that incorporate benzoxazine, quinoxaline, quinoline and 1,2,4-triazine moieties. It was reasoned that this type of molecular combination might lead to finding compounds with improved antitumor activity.

Results and discussion

Chemistry

The target compounds were synthesized as depicted in Scheme 1 and Equations 1–2. The key intermediate, 1-(1*H*-benzimidazol-2-yl)-2-bromoethanone (1), was synthesized as previously reported [24]. Treatment of **1** with the appropriate substituted anilines gave the corresponding products **2–5** (Scheme 1). The reaction of **1** with sodium benzoate or its 2-hydroxy derivative yielded the respective benzoate **6** or **7**. In addition, the desired hydrazides **8** and **9** were synthesized by treatment of the substrate **1** with the appropriate hydrazides. By contrast, the reaction of **1** with 1,2-phenylenediamine or 2-aminophenol gave 3-(1*H*-benzimidazol-2-yl)-1,2-dihydroquinoxaline (**10**) and 3-(1*H*-benzimidazol-2-yl)-2*H*-benzo[*b*][1,4]oxazine (**11**), respectively. All compounds **2–11** were fully characterized by spectroscopic methods and elemental analysis.

Known 2-acetylimidazoles **12a,b** [25] were allowed to react with isatins to furnish the desired 2-(1*H*-benzimi-dazole-2-yl)-6-substituted quinoline-4-carboxylic acids **13–15** (Equation 1).



^{*}Corresponding author: Sahar Badr, Faculty of Pharmacy, Department of Pharmaceutical Organic Chemistry, University of Mansoura, Mansoura 35516, Egypt, e-mail: saharmbadr@yahoo.com Atif Tantawy, Alaa-eldin Barghash and Rania Gomaa: Faculty of Pharmacy, Department of Pharmaceutical Organic Chemistry, University of Mansoura, Mansoura 35516, Egypt



Figure 1 Structures of some antitumor drugs containing benzimidazole moiety.

Finally, the substrates **16a** [26–28] and **16b** were used in the preparation of benzimidazo[1,2-*d*][1,2,4]triazine-4-carbonitriles **17–24** (Equation 2). Again, the given structures of the synthesized compounds **12–24** were fully consistent with the spectroscopic and elemental analysis data.



Scheme 1



Biology

All compounds **2–15** and **17–24** were evaluated for their *in vitro* antitumor activity against human MCF7 cell line (breast cancer) using a one dose primary anticancer *in vitro* assay [29, 30]. The results are presented in Table 1. The requirement for antitumor activity set by the National Cancer Institute is that the fraction of surviving tumor cells is 30% or less, which corresponds to inhibition of 70% or more. According to this definition it may be concluded that compounds **13–15** and **24** are active.

The IC_{50} values for the active compounds **13–15** and **24** are also given in Table 1.

Conclusion

A series of benzimidazoles **2–11**, **13–15** and **17–24** were synthesized and evaluated for their *in vitro* antitumor activity against MFC7 cell line. Compounds **13–15** and **24** exhibit significant activity.

Table 1 Antitumor activity of compounds 2–11, 13–15 and 17–24 against MCF7 cell line.

Compound	% Surviving	% Inhibition	IC_{50}^{b} , $\mu g/mL$
2	40.5	59.5	
3	33.2	66.8	
4	32.9	67.1	
5	48.4	51.6	
6	39.5	60.5	
7	34.3	65.7	
8	31.2	68.8	
9	30.8	69.2	
10	47.4	52.6	
11	42.7	57.3	
13	28.1	71.9ª	16.3
14	26.0	74.0ª	15.5
15	27.0	73.0ª	12.7
17	41.4	58.6	
18	32.9	67.1	
19	40.6	59.4	
20	34.4	65.6	
21	37.1	62.9	
22	32.8	67.2	
23	33.2	66.8	
24	29.9	70.1ª	16.7

 $^{\rm a} \rm Compounds$ showing significant antitumor activity. $^{\rm b} \rm IC_{50}$ for active antitumor compounds.

Experimental

General

Unless otherwise noted, all materials were obtained from commercial suppliers (Aldrich and Merck companies) and used without further purification. Melting points were recorded using an Electrothermal C14500 apparatus and were uncorrected. Microanalyses were performed at the microanalytical unit, Cairo University. IR spectra were recorded on a Mattson 5000 FT-IR spectrometer using KBr disks. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded on a Bruker Avance-400 spectrometer in DMSO- d_6 at Georgia State University, Atlanta, GA, USA and the Korea Institute of Science and Technology, Republic of Korea. Mass spectral analyses were performed on a JOEL JMS-600H spectrometer at Cairo University. Reaction progress was monitored using TLC on silica gel plates 60 F_{245} E. Merck, and the spots were visualized by UV light at 366 nm or 245 nm. Substrates 1 [24], **12a,b** [25] and **16a** [26–28] were synthesized according to reported methods.

1-(1*H*-Benzimidazol-2-yl)-2-[(substituted phenyl)amino]ethanones 2–5

A mixture of 1-(1*H*-benzimidazol-2-yl)-2-bromoethanone **1** [24] (0.5 g, 0.002 mol), a substituted aniline (0.002 mol) and sodium bicarbonate (1.55 g) in anhydrous ethanol (50 mL) was heated under reflux for 4 h. Then the mixture was allowed to cool to room temperature and the resultant precipitate was filtered, washed thoroughly with water,

dried and crystallized from absolute ethanol to afford the title compound **2–5**.

1-(1*H***-Benzimidazol-2-yl)-2-[(4-bromophenyl)amino]ethanone (2)** Yellow compound; yield 68%; mp 158–160°C; ¹H NMR: δ 4.40 (s, 2H, CH₂), 6.28 (s, 1H, NH, D₂O exchangeable), 6.48 (d, J = 8, 2H), 7.12 (d, J = 8, 2H), 7.24 (d, J = 8.7, 2H), 7.66 (d, J = 8.7, 2H), 12.81 (s, 1H, NH, D₂O exchangeable); MS: m/z 330 [M⁺], 332 [M⁺+2]. Anal. Calcd for C₁₅H₁₂BrN₃O: C, 54.56; H, 3.66; N, 12.73. Found: C, 54.49; H, 3.61; N, 12.82.

1-(1*H***-Benzimidazol-2-yl)-2-[(4-chlorophenyl)amino]ethanone** (**3**) Yellowish brown compound; yield 72%; mp 182–184°C; [']H NMR: δ 5.12 (s, 2H, CH₂), 6.24 (s, 1H, NH, D₂O exchangeable), 6.54 (d, *J* = 7.5, 2H), 7.17 (d, *J* = 7.5, 2H), 7.27 (d, *J* = 8.7, 2H), 7.59 (d, *J* = 8.7, 2H), 12.81 (s, 1H, NH, D₂O exchangeable); MS: m/z 285 [M⁺], 287 [M⁺+2]. Anal. Calcd for C₁₅H₁₂ClN₃O: C, 63.05; H, 4.23; N, 14.71. Found: C, 63.11; H, 4.17; N, 14.68.

1-(1H-Benzimidazol-2-yl)-2-[(4-methoxyphenyl)amino]ethanone (4) Brown compound; yield 70%; mp 199–201°C; ¹H NMR: δ 3.80 (s, 3H, OCH₃), 4.19 (s, 2H, CH₂), 6.50 (s, 1H, NH, D₂O exchangeable), 6.70 (d, J = 7.8, 2H), 6.90 (d, J = 7.8, 2H), 7.22 (d, J = 8.4, 2H), 7.59 (d, J = 8.4, 2H), 12.81 (s, 1H, NH, D₂O exchangeable); MS: m/z 281 [M⁺]. Anal. Calcd for C₁₆H₁₅N₃O₂: C, 68.31; H, 5.37; N, 14.94. Found: C, 68.24; H, 5.45; N, 15.03.

1-(1H-Benzimidazol-2-yl)-2-[(2-methylthiophenyl)amino]ethanone (5) Brown compound; yield 79%; mp 151–153°C; ¹H NMR: δ 2.33 (s, 3H, SCH₃), 5.18 (s, 2H, CH₂), 6.22 (s, 1H, NH, D₂O exchangeable), 6.28 (t, *J* = 7.8, 1H), 6.57 (t, *J* = 7.8, 1H), 6.82 (d, *J* = 7.8, 1H), 7.10 (d, *J* = 7.8, 1H), 7.22 (d, *J* 8.7, 2H), 7.59 (d, *J* = 8.7, 2H), 12.81 (s, 1H, NH, D₂O exchangeable); MS: m/z 297 [M⁺]. Anal. Calcd for C₁₆H₁₅N₃OS: C, 64.62; H, 5.08; N, 14.13. Found: C, 64.66; H, 5.13; N, 14.09.

1-(1*H*-Benzimidazol-2-yl)-2-oxoethyl benzoates 6, 7

Sodium benzoate or sodium 2-hydroxybenzoate (0.002 mol) was added at room temperature to a solution of 1-(1*H*-benzimidazol-2-yl)-2-bromoethanone **1** [24] (0.5 g, 0.002 mol) in DMF. Stirring at room temperature was continued for another 8 h. Then the mixture was poured into water and the precipitated product was filtered, washed thoroughly with water, dried and crystallized from DMF to afford the title compound **6**, **7**.

1-(1H-Benzimidazol-2-yl)-2-oxoethyl benzoate (6) Orange compound; yield 72%; mp 136–138°C; IR: 1660 (-CO-CH₂), 1740 (-COO-CH₂), 2985, 2960 (CH₂), 3150 cm⁻¹ (NH); ¹H NMR: δ 5.86 (s, 2H, CH₂), 7.22 (d, *J* = 8.7, 2H), 7.46 (t, *J* = 8Hz, 1H), 7.59 (d, *J* = 8.7, 2H), 7.66 (t, *J* = 8Hz, 2H), 8.03 (d, *J* = 8Hz, 2H), 12.01 (s, 1H, NH, D₂O exchangeable); MS: m/z 280 [M⁺]. Anal. Calcd for C₁₆H₁₂N₂O₃; C, 68.56; H, 4.32; N, 9.99. Found: C, 68.51; H, 4.28; N, 10.11.

1-(1H-Benzimidazol-2-yl)-2-oxoethyl 2-hydroxybenzoate (7) Yellow compound; yield 75%; mp 158–160°C; lR: 1650 (-CO-CH₂), 1740 (-COO-CH₂), 2940, 2875 (CH₂), 3100 (NH), 3500 cm⁻¹ (OH); ¹H NMR: δ 5.89 (s, 2H, CH₂), 6.88 (d, *J* = 7.7 Hz, 1H), 7.01 (t, *J* = 7.7 Hz, 1H), 7.12 (t, *J* = 7.7 Hz, 1H), 7.24 (d, *J* = 8.7 Hz, 2H), 7.59 (d, *J* = 8.7 Hz, 2H), 7.88 (d, *J* = 7.7 Hz, 1H), 10.29 (s, 1H, OH), 12.01 (s, 1H, NH, D₂O exchangeable); ¹³C NMR: δ 60.2, 111.6, 114.3, 116.2, 120.2, 122.1, 129.2, 130.1, 132.4, 150.2, 155.1, 160.9, 163.2; MS: m/z 296 [M⁺]. Anal. Calcd for C₁₆H₁₂N₂O₄: C, 64.86; H, 4.08; N, 9.46. Found: C, 64.91; H, 4.11; N, 9.39.

N'-[2-(1*H*-Benzimidazol-2-yl)-2-oxoethyl] benzohydrazides 8, 9

A mixture of 1-(1*H*-benzimidazol-2-yl)-2-bromoethanone **1** [24] (0.5 g, 0.002 mol), an acid hydrazide (0.002 mol) and sodium bicarbonate (1.55 g) in absolute ethanol (50 mL) was heated under reflux for 6 h. Then the mixture was allowed to cool to room temperature and the resulting precipitate was filtered, washed thoroughly with water, dried and crystallized from absolute ethanol to afford the title compound **8**, **9**.

N'-[**2-(1***H*-**Benzimidazol-2-yl)-2-oxoethyl]benzohydrazide (8)** Yellow compound; yield 74%; mp 150–152°C; IR: 1662 (-CO-CH₂), 1685 (C=O hydrazino), 2960, 2890 (CH₂), 3150, 3350, 3410 cm⁻¹ (NH); ¹H NMR: δ 3.34 (s, 2H, CH₂), 5.0 (s, 1H, NH, D₂O exchangeable), 7.22 (d, *J* = 8.7 Hz, 2H), 7.42 (t, *J* = 8 Hz, 2H), 7.59 (d, *J* = 8.7 Hz, 2H), 7.63 (t, *J* = 8 Hz, 1H), 7.84 (d, *J* = 8 Hz, 2H), 8.0 (s, 1H, NH, D₂O exchangeable), 12.10 (s, 1H, NH, D₂O exchangeable); MS: m/z 294 [M⁺]. Anal. Calcd for C₁₆H₁₄N₄O₂: C, 65.30; H, 4.79; N, 19.04. Found: C, 65.37; H, 4.71; N, 19.13.

 $N' - [2 - (1 H - B e n z i m i d a z o l - 2 - y l) - 2 - o x o e t h y l] - 2 - hydroxybenzohydrazide (9) Yellow compound; yield 71%; mp 177–179°C; IR: 1662 (-CO-CH₂), 1685 (C=O hydrazino), 2972, 2860 (CH₂), 3150, 3350, 3410 (NH), 3500 cm⁻¹ (OH); ¹H NMR: <math>\delta$ 3.34 (s, 2H, CH₂), 5.0 (s, 1H, NH, D₂O exchangeable), 6.95 (d, J = 7.7 Hz, 1H), 7.03 (t, J = 7.7 Hz, 1H), 7.22 (d, J = 8.7 Hz, 2H), 7.32 (t, J = 7.7 Hz, 1H), 7.59 (d, J = 8.7 Hz, 2H), 7.86 (d, J = 7.7 Hz, 1H), 8.0 (s, 1H, NH, D₂O exchangeable), 11.50 (s, 1H, OH), 12.10 (s, 1H, NH, D₂O exchangeable); MS: m/z 310 [M⁺]. Anal. Calcd for C₁₆H₁₄N₄O₃: C, 61.93; H,4.55; N, 18.06. Found: C, 61.99; H, 4.50; N, 17.97.

3-(1*H*-Benzimidazol-2-yl)-1,2-dihydroquinoxaline (10) and 3-(1*H*-benzimidazol-2-yl)-2*H*-benzo[*b*][1,4]oxazine (11)

A mixture of 1-(1*H*-benzimidazol-2-yl)-2-bromoethanone **1** [24] (0.01 mol), 1,2-phenylenediamine or 2-aminophenol (0.011 mol), and ethanol (20 mL) was heated under reflux for 3 h. After cooling, the separated solid was filtered and washed with ethanol. The precipitate was then suspended in water, stirred with saturated sodium bicarbonate solution (30 mL, 5%), filtered, washed thoroughly with water, dried and crystallized from ethyl acetate/ethanol (1:1) to afford the title compound **10** or **11**.

3-(1H-Benzimidazol-2-yl)-1,2-dihydroquinoxaline (10) Yellow compound; yield 79%; mp 227–229°C; ¹H NMR: δ 3.2 (s, 2H, CH₂), 5.0 (s, 1H, NH, D₂O exchangeable), 6.89 (d, *J* = 8.8 Hz, 1H), 7.01 (t, *J* = 8.8 Hz, 1H), 7.22 (d, *J* = 8.4 Hz, 2H), 7.32 (t, *J* = 8.8 Hz, 1H), 7.45 (d, *J* = 8.8 Hz, 1H), 7.59 (d, *J* = 8.4 Hz, 2H), 12.0 (s, 1H, NH, D₂O exchangeable); MS: m/z 248 [M⁺]. Anal. Calcd for C₁₅H₁₂N₄: C, 72.56; H, 4.87; N, 22.57. Found: C, 72.62; H, 4.75; N, 22.69.

3-(1H-Benzimidazol-2-yl)-2H-benzo[b][1,4]oxazine (11) Brown compound; yield 76%; mp 211–213°C; 'H NMR: δ 4.0 (s, 2H, CH₂), 6.68 (d, *J* = 8.2 Hz, 1H), 7.02 (t, *J* = 8.2 Hz, 1H), 7.22 (d, *J* = 8.7 Hz, 2H), 7.43 (t, *J* = 8.2 Hz, 1H), 7.59 (d, *J* = 8.7 Hz, 2H), 7.81 (d, *J* = 8.2 Hz, 1H), 12.01 (s, 1H, NH, D₂O exchangeable); MS: m/z 249 [M⁺]. Anal. Calcd for C₁₅H₁N₃O: C, 72.28; H, 4.45; N, 16.86. Found: C, 72.21; H, 4.34; N, 16.82.

2-(1*H*-Benzimidazol-2-yl)quinoline-4-carboxylic acids 13–15

A solution of potassium hydroxide (1.02 g, 0.018 mol) in water (5 mL) was added dropwise to the appropriate isatin derivatives (0.003 mol) in ethanol (10 mL) over 15 min. The appropriate benzimidazole derivatives **12a,b** [25] (0.003 mol) were added and the reaction mixture was heated under reflux for 18 h, then cooled to room temperature and the solvent was removed under vacuum. The resulting solid was dissolved in water, washed with diethyl ether, cooled in ice-cold water and acidified with acetic acid. The separated solid was filtered and recrystallized from acetic acid to afford the title compounds **13–15**.

2-(1*H***-Benzimidazol-2-yl)-6-chloroquinoline-4-carboxylic acid (13)** Yellow compound; yield 69%; mp 257–259°C; IR: 1725 (CO), 3200 (NH), 3400 cm⁻¹ (OH); ¹H NMR: δ 7.22 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 2H), 7.86 (d, *J* = 8.6 Hz, 1H), 8.26 (d, *J* = 8.6 Hz, 1H), 8.47 (s, 1H), 9.07 (s, 1H), 12.81 (s, 1H, NH, D₂O exchangeable), 13.21 (s, 1H, COOH); ¹³C NMR: δ 114.8, 122.3, 123.1, 124.0, 124.5, 126.8, 129.0, 130.1, 133.2, 140.2, 145.1, 152.7, 154.2, 162.1; MS: m/z 323 [M⁺], 325 [M⁺+2]. Anal. Calcd for C₁₇H₁₀ClN₃O₂: C, 63.07; H, 3.11; N, 12.98. Found: C, 62.96; H, 3.18; N, 13.09.

2-[(5-Methyl)-1*H***-benzimidazol-2-yl]quinoline-4-carboxylic acid (14)** Buff compound; yield 70%; mp 133–135°C; IR: 1725 (CO), 3200 (NH), 3500 cm⁻¹ (OH); ¹H NMR: δ 2.44 (s, 3H, CH₃), 7.15 (d, *J* = 8.4 Hz, 1H), 7.33 (s, 1H), 7.52 (d, *J* = 8.4 Hz, 1H), 7.86 (t, *J* = 8.6 Hz, 1H), 7.98 (d, *J* = 8.6 Hz, 1H), 8.10 (t, *J* = 8.6 Hz, 1H), 8.20 (d, *J* = 8.6 Hz, 1H), 8.47 (s, 1H), 12.77 (s, 1H, NH, D₂O exchangeable), 13.19 (s, 1H, COOH); ¹³C NMR: δ 20.8, 114.5, 119.2, 122.8, 124.5, 124.9, 126.5, 128.0, 128.8, 130.0, 135.4, 135.7, 138.2, 145.1, 152.7, 153.2, 162.8; MS: m/z 303 [M⁺]. Anal. Calcd for C₁₈H₁₃N₃O₂: C, 71.28; H, 4.32; N, 13.85. Found: C, 71.36; H, 4.25; N, 13.71.

2-(5-Methyl-1H-benzimidazol-2-yl)-6-methylquinoline-4-carboxylic acid (15) Yellow compound; yield 65%; mp 204–206°C; IR: 1725 (CO), 3200 (NH), 3500 cm⁻¹ (OH); ¹H NMR: δ 2.51 (s, 6H, 2CH₃), 7.12 (d, *J* = 8.4 Hz, 1H), 7.32 (s, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.76 (d, *J* = 8.6 Hz, 1H), 8.16 (d, *J* = 8.6 Hz, 1H), 8.36 (s, 1H), 8.48 (s, 1H), 12.81 (s, 1H, NH, D₂O exchangeable), 13.21 (s, 1H, COOH); ¹³C NMR: δ 20.7, 20.9, 114.9, 122.1, 123.0, 124.2, 125.1, 128.2, 129.4, 132.1, 132.4, 134.2, 134.8, 137.8, 144.2, 152.1, 152.4, 163.7; MS: m/z 317 [M⁺]. Anal. Calcd for C₁₉H₁₅N₃O₂: C, 71.91; H, 4.76; N, 13.24. Found: C, 72.12; H, 4.72; N, 13.28.

Ethyl 2-cyanomethyl-5-methyl-1*H*-benzimidazole-1-carboxylate (16b)

A solution of 5-methyl-2-cyanomethylbenzimidazole [27, 28] (0.01 mol) in pyridine (20 mL) was stirred in an ice bath and treated drop-

wise with ethyl chloroformate (2.7 g, 0.025 mol). Stirring was continued for an additional 10 min and then the mixture was poured on cold water (400 mL). The resultant precipitate of **16b** was collected by filtration, dried and crystallized from ethanol: yellow compound; yield 74%; mp 76–78°C; IR: 2220 (CN), 1715 (CO), 1620 cm⁻¹ (C=N); ¹H NMR: δ 1.25 (t, *J* = 7 Hz, 3H, CH₂CH₃), 2.34 (s, 3H, CH₃), 3.67 (s, 2H, CH₂-CN), 4.17 (q, *J* = 7 Hz, 2H, CH₂CH₃), 7.12 (d, *J* = 8.7 Hz, 1H), 7.33 (s, 1H), 7.54 (d, *J* = 8.7 Hz, 1H); MS: m/z 243 [M⁺]. Anal. Calcd for C₁₃H₁₃N₃O₂: C, 64.19; H, 5.39; N, 17.27. Found: C, 64.24; H, 5.45; N, 17.33.

1-Oxo-2-(substituted phenyl)-1,2-dihydrobenzimidazo[1,2-*d*][1,2,4]triazine-4-carbonitriles 17–24

To a solution of **16a** [26] or **16b** (0.01 mol) in pyridine (20 mL) in an ice bath, a solution of a diazonium hydrochloride [amine (0.01 mol), 36% HCl (3 mL), ice water (10 mL) and $NaNO_2$ (0.7 g, 0.01 mol)] was added with stirring. After 24 h, the mixture was diluted with ice-cold water (200 mL), and the resultant precipitate of **17–24** was collected by filtration, dried and crystallized.

1-Oxo-2-(2-chlorophenyl)-1,2-dihydrobenzimidazo[1,2-d][1,2,4] triazine-4-carbonitrile (17) Crystallized from absolute ethanol; yellow compound; yield 71%; mp 151–153°C; IR: 1600, 1640 (C=N), 1700 (CO), 2220 cm⁻¹ (C=N); ¹H NMR: δ 7.63 (d, *J* = 8.4 Hz, 2H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.92 (t, *J* = 7.5 Hz, 1H), 8.01 (t, *J* = 7.5 Hz, 1H), 8.15 (d, *J* = 7.5 Hz, 1H), 8.35 (d, *J* = 7.5 Hz, 1H); MS: m/z 321 [M⁺], 323 [M⁺+2]. Anal. Calcd for C₁₆H₈ClN₅O: C, 59.73; H, 2.51; N, 21.77. Found: C, 59.60; H, 2.55; N, 21.73.

1-Oxo-2-(3-chlorophenyl)-1,2-dihydrobenzimidazo[1,2-d][1,2,4] triazine-4-carbonitrile (18) Crystallized from absolute ethanol; orange compound; yield 69%; mp 183–185°C; IR: 1600, 1640 (C=N), 1680 (CO), 2225 cm⁻¹ (C=N); ¹H NMR: δ 7.63 (d, *J* = 8.4 Hz, 2H), 7.72 (d, *J* = 8.4 Hz, 2H),7.88 (t, *J* = 7.5 Hz, 1H), 8.11 (d, *J* = 7.5 Hz, 1H), 8.28 (d, *J* = 7.5 Hz, 1H), 8.37 (s, 1H); MS: m/z 321 [M⁺], 323 [M⁺+2]. Anal. Calcd for C₁₆H₈ClN₅O: C, 59.73; H, 2.51; N, 21.77. Found: C, 59.79; H, 2.48; N, 21.69.

1-Oxo-2-(4-methoxylphenyl)-1,2-dihydrobenzimidazo[1,2-d] [1,2,4]triazine-4-carbonitrile (19) Crystallized from methanol; orange compound; yield 75%; mp 200–202°C; IR: 1605, 1640 (C=N), 1680 (CO), 2225 cm⁻¹ (C=N); ¹H NMR: δ 3.86 (s, 3H, OCH₃), 7.02 (d, *J* = 7.8 Hz, 2H), 7.62 (d, *J* = 8.7 Hz, 2H), 7.91 (d, *J* = 8.7 Hz, 2H), 8.35 (d, *J* = 7.8 Hz, 2H); MS: m/z 317 [M⁺]. Anal. Calcd for C₁₇H₁₁N₅O₂: C, 64.35; H, 3.49; N, 22.07. Found: C, 64.44; H, 3.45; N, 22.17.

1-Oxo-2-(2-thiomethylphenyl)-1,2-dihydrobenzimidazo[1,2-d] [1,2,4]triazine-4-carbonitrile (20) Crystallized from absolute ethanol; yellow compound; yield 66%; mp 194–196°C; IR: 1560, 1614 (C=N), 1743 (C=O), 2220 cm⁻¹ (C=N); ¹H NMR: δ 2.51 (s, 3H, S-CH₃), 7.44 (d, *J* = 8.7 Hz, 2H), 7.62 (d, *J* = 7.8 Hz, 1H), 7.80 (t, *J* = 7.8 Hz, 1H), 7.91 (t, *J* = 7.8 Hz, 1H), 8.04 (d, *J* = 8.7 Hz, 2H), 8.36 (d, *J* = 7.8 Hz, 1H); MS: m/z 333 [M⁺]. Anal. Calcd for C₁₇H₁₁N₅OS: C, 61.25; H, 3.33; N, 21.01. Found: C, 61.33; H, 3.28; N, 21.07.

8-Methyl-1-oxo-2-(2-chlorophenyl)-1,2-dihydrobenzimidazo[1,2*d*][1,2,4]triazine-4-carbonitrile (21) Crystallized from absolute ethanol; yellow compound; yield 72%; mp 150–152°C; IR: 1600, 1630 (C=N), 1700 (C=O), 2225 cm¹ (C=N); ¹H NMR: δ 2.47 (s, 3H, CH₃), 7.39 (d, *J* = 8.4 Hz, 1H), 7.52 (t, *J* = 7.5 Hz, 1H), 7.71 (t, *J* = 7.5 Hz, 1H), 7.90 (d, *J* = 7.5 Hz, 1H), 8.0 (d, *J* = 8.4 Hz, 1H), 8.12 (d, *J* = 7.5 Hz, 1H), 8.0 (d, *J* = 8.4 Hz, 1H), 8.12 (d, *J* = 7.5 Hz, 1H), 8.21 (s, 1H); MS: m/z 335 [M⁺], 337 [M⁺+2]. Anal. Calcd for C₁₇H₁₀ClN₅O: C, 60.81; H, 3.00; N, 20.86. Found: C, 60.89; H, 3.12; N, 20.71.

8-Methyl-1-oxo-2-(3-chlorophenyl)-1,2-dihydrobenzimidazo[1,2d][1,2,4]triazine-4-carbonitrile (22) Crystallized from methanol, yellowish brown compound; yield 88%; mp 147–149°C; IR: 1605, 1640 (C=N), 1700 (C=O), 2220 cm⁴ (C=N); ¹H NMR: δ 2.43 (s, 3H, CH₃), 7.39 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 7.5 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.91 (d, J = 7.5 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 8.12 (s, 1H), 8.21 (s, 1H); MS: m/z 335 [M⁺], 337 [M⁺+2]. Anal. Calcd for C₁₇H₁₀ClN₅O: C, 60.81; H, 3.00; N, 20.86. Found: C, 60.87; H, 3.09; N, 20.89.

8-Methyl-1-oxo-2-(4-methoxyphenyl)-1,2-dihydrobenzimidazo [1,2-d][1,2,4]triazine-4-carbonitrile (23) Crystallized from absolute ethanol, buff compound; yield 85%; mp 166–168°C; IR: 1600, 1640 (C=N), 1680 (C=O), 2220 cm⁻¹ (C=N); ¹H NMR: δ 2.56 (s, 3H, CH₃), 3.85 (s, 3H, O-CH₃), 7.12 (d, *J* = 7.8 Hz, 2H), 7.44 (d, *J* = 7.8 Hz, 2H), 7.69 (d, *J* = 8.4 Hz, 1H), 7.84 (d, *J* = 8.4 Hz, 1H), 8.15 (s, 1H); ¹³C NMR: 20.9, 55.0, 111.7, 113.7, 113.9, 119.9, 127.2, 127.6, 128.4, 131.9, 136.3, 140.7, 159.0; MS: m/z 331 [M⁺]. Anal. Calcd for C₁₈H₁₃N₅O₂: C, 65.25; H, 3.95; N, 21.14. Found: C, 65.20; H, 3.87; N, 21.18.

8-Methyl-1-oxo-2-(2-thiomethylphenyl)-1,2-dihydrobenzimidazo [1,2-d][1,2,4]triazine-4-carbonitrile (24) Crystallized from aqueous ethanol; brown compound; yield 77%; mp 162–164°C; IR: 1600, 1630 (C=N), 1700 (C=O), 2220 cm⁻¹ (C=N); ¹H NMR: δ 2.34 (s, 3H, CH₃), 2.53 (s, 3H, S-CH₃), 7.42 (d, *J* = 7.8 Hz, 1H), 7.60 (t, *J* = 7.8 Hz, 1H), 7.78 (t, *J* = 7.8 Hz, 1H), 7.86 (d, *J* = 8.4 Hz, 1H), 7.91(d, *J* = 7.8 Hz, 1H), 8.11 (d, *J* = 8.4 Hz, 1H), 8.20 (s, 1H); MS: m/z 347 [M⁺]. Anal. Calcd for C₁₈H₁₃N₅OS: C, 62.23; H, 3.77; N, 20.16. Found: C, 62.34; H, 3.73; N, 20.19.

Biology

All materials were obtained from Sigma Chemical Co. (USA). Human tumor cell lines were obtained frozen in liquid nitrogen (-180°C) from the American Type Culture Collection. The tumor cell lines were maintained in the National Cancer Institute, Cairo, Egypt, by serial subculturing. In vitro antitumor activity against human MCF7 (breast cancer cell line) was determined using the Sulforhodamine B assay [29, 30]. Cells were plated in a 96-multiwell plate (10⁴ cells/well) for 24 h before treatment with the compounds to allow attachment of the cell to the wall of the plate. Monolayer cells were incubated with the compounds for 48 h at 37°C in a humidified incubator with 5% CO₂. Cells were fixed with trichloroacetic acid and stained for 30 min with 0.4% (wt/vol) Sulforhodamine B (SRB) stain dissolved in 1% acetic acid. Unbound dye was washed with 1% acetic acid and protein bound dye was extracted with Tris EDTA. The optical density (OD) of each well was measured spectrophotometrically at 564 nm with an ELISA microplate reader (Meter tech. Σ 960, USA). Cell survival was calculated as follows: survival fraction = OD (treated cells)/OD (control cells) (Table 1). For determination of IC₅₀, different concentrations of the compound under test (0, 1, 2.5, 5 and 10 µg/mL) were added to the cell monolayer wells which were prepared for each individual dose. The absorbance of each well was determined by an ELISA reader. The relation between surviving fraction and compound concentration was plotted to obtain

the survival curve of the tumor cell line after the specified compound (Table 1).

Acknowledgments: The authors would like to express their gratitude and thanks to the National Cancer Institute (NCI), Cancer Biology Department, Pharmacology Unit, Cairo University, Egypt for performing antitumor activity.

Received January 20, 2013; accepted January 28, 2013; previously published online March 21, 2013

References

- EL-Naggar, S. A.; El-Barbary, A. A.; Mansour, M. A.; Abdel-Shafy, F.; Talat, S. Anti-tumor activity of some 1,3,4-thiadiazoles and 1,2,4-triazine derivatives against Ehrlichs ascites carcinoma. *Int. J. Cancer Res.* 2011, *7*, 278–288.
- [2] Patel, O. B.; Patel, L. J. Microwave assisted synthesis and biological evaluation of benzimidazole derivatives as anticancer agents. *Int. J. Pharm. Appl. Sci.* 2011, 2, 15–19.
- [3] Xiang, P.; Zhou, T.; Wang, L.; Sun, C. Y.; Hu, J.; Zhao, Y. L.; Yang, L. Novel benzothiazole, benzimidazole and benzoxazole derivatives as potential antitumor agents: synthesis and preliminary in vitro biological evaluation. *Molecules* 2012, *17*, 873–883.
- [4] Algul, O.; Ozc, B.; Abbasoglu, U.; Gumus, F. Synthesis, characterization and genotoxicity of platinum(II)complexes with substituted benzimidazole ligands. *Turk. J. Chem.* 2005, 29, 607–615.
- [5] Siddiqui, N.; Bhrigu, B.; Pathak, D. R.; Alam, M. S. R.; Ali, R. Cytotoxicity and enzymes estimation of some newer benzimidazoles. *Ann. Biol. Res.* 2011, *2*, 194–199.
- [6] Abdel-Hafez, A. A. Benzimidazole condensed ring systems: new synthesis and antineoplastic activity of substituted 3,4-dihydro and 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a] pyrimidine derivatives. *Arch. Pharm. Res.* 2007, 30, 678–684.
- [7] Alpan, A. S.; Gunes, H. S.; Topcu, Z. 1*H*-Benzimidazole derivatives as mammalian DNA topoisomerase l inhibitors. *Anticancer Res.* 2007, *54*, 561–565.
- [8] Nofal, Z. M.; Soliman, E. A.; Abdelkarim, S. S.; Elzahar, M. I.; Srour, A. M.; Sethumadhavan, S.; Maher, T. J. Novel benzimidazole derivatives as expected anticancer agents. *Acta Pol. Pharm. Drug Res.* 2011, *68*, 519–534.
- [9] Ramla, M. M.; Omar, M. A.; Elkhamry, A. M.; Eldiwani, H. I. Synthesis and antitumor activity of 1-substituted-2-methyl-5-nitrobenzimidazoles. *Bioorg. Med. Chem.* 2006, 14, 7224–7332.
- [10] Nawrocka, W.; Sztuba, B.; Kowalska, M. W.; Liszkiewicz, H.; Wietrzyk, J.; Nasulewicz, A.; Pelczynska, M.; Opolski, A. Synthesis and antiproliferative activity in vitro of 2-aminobenzimidazole derivatives. *IL Farmaco* 2004, *59*, 83–91.
- [11] Leoni, L. M. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. *Semin. Hematol.* 2011, 48, 4–11.

- [12] Alper, S.; Arpaci, O. T.; Aki, E. S.; Yalc, I. Some new bi- and ter-benzimidazole derivatives as topoisomerase I inhibitors. *IL Farmaco* 2003, *58*, 497–507.
- [13] Varga, A.; Akisener, E.; Yalcin, I.; Temizarpaci, O.; Tekinergulbas, B.; Cherepnev, G.; Molnar, J. Induction of apoptosis and necrosis by resistance modifiers benzazoles and benzoxazines on tumour cell line mouse lymphoma L5718 cells. *In Vivo* 2005, 19, 1087–1092.
- [14] Korolyov, A.; Dorbes, S.; Azema, J.; Guidetti, B.; Danel, M.; Theys, D. L.; Gras, T.; Dubois, J.; Kiss, R.; Martino, R.; et al. Novel lipophilic 7H-pyrido[1,2,3-de]-1,4-benzoxazine-6carboxylic acid derivatives as potential antitumor agents: improved synthesis and in vitro evaluation. *Bioorg. Med. Chem.* 2010, 18, 8537–8548.
- [15] Ghorab, M. M.; Ragab, F. A.; Heiba, H. I.; Elgazzar, M. G. Synthesis, in vitro anticancer screening and radiosensitizing evaluation of some new 4-[3-(substituted)thioureido]-*N*-(quinoxalin-2-yl)benzenesulfonamide derivatives. *Acta Pharm.* 2011, *61*, 415–425.
- [16] Noolvi, M. N.; Patel, H. M.; Bhardwaj, V.; Chauhan, A. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent. *Eur. J. Med. Chem.* 2011, 46, 2327–2346.
- [17] Abuhashem, A. A.; Aly, A. S. Synthesis of new pyrazole, triazole, and thiazolidine-pyrimido [4,5-b] quinoline derivatives with potential antitumor activity. *Arch. Pharm. Res.* 2012, *35*, 437–445.
- [18] Srivastava, S. K.; Jha, A.; Agarwal, S. K.; Mukherjee, R.; Burman, A. C. Synthesis and structure activity relationships of potent antitumor active quinoline and naphthyridine derivatives. *Anticancer Agents Med. Chem.* 2007, *7*, 685–709.
- [19] Rashad, A. E.; Elsayed, W. A.; Mohamed, A. M.; Ali, M. M. Synthesis of new quinoline derivatives as inhibitors of human tumor cells growth. Arch. Pharm. 2010, 343, 440–448.
- [20] Utsugi, T.; Aoyagi, K.; Asao, T.; Okazaki, S.; Aoyagi, Y.; Sano, M.; Wierzba, K.; Yamada, Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. *Jpn. J. Cancer Res.* **1997**, *88*, 992–1002.
- [21] Sztanke, K.; Pasternak, K.; Rzymowska, J.; Sztanke, M.; Szerszen, M. K. Synthesis, structure elucidation and identification of antitumor properties of novel fused 1,2,4-triazine aryl derivatives. *Eur. J. Med. Chem.* 2008, 43, 1085–1094.

- [22] Ruel, R.; Thibeault, C.; Heureux, A. L.; Martel, A.;
 Cai, Z. W.; Wei, D.; Qian, L.; Barrish, J. C.; Mathur, A.;
 Arienzo, C. D.; et al. Discovery and preclinical studies of
 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-*N*-(2-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)pyrrolo[2,1-*f*][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent
 VEGFR-2 inhibitor. *Bioorg. Med. Chem. Lett.* 2008, 18, 2985–2989.
- [23] Sharma, N. K.; Kumar, Y.; Sahi, S. 3D QSAR studies of pyrrolo[2,1-f][1,2,4] triazines as tyrosine kinase inhibitors. *Int. J. Pharm. Pharm. Sci.* 2010, *2*, 118–121.
- [24] Serafin, B.; Szymanowska, E. Benzimidazole derivatives. Part
 I. Bromination of 2-acetyl benzimidazoles and its derivatives. *Roczn. Chem.* 1975, 49, 791–798.
- [25] Cheeseman, G. W. H. 2-Acetylbenzimidazole. J. Chem. Soc. 1964, 4645–4646.

- [26] Slouka, J. Cyclisierungsreaktionen von hydrazonen I. Synthese von 1-oxo-2-aryl-1,2-dihydro-(as-triazino)[5,4-a]benzimidazol-4-carbonsäurenitrilen. *Tetrahedron Lett.* **1968**, *9*, 4007–4008.
- [27] Ralph, A. B.; Allan, R. D. The preparation and reactions of 2-benzimidazolecarboxylic acid and 2-benzimidazoleacetic acid. J. Am. Chem. Soc. 1943, 65, 1072–1075.
- [28] Sawlewicz, J.; Milczarska, B. Reactions of cyanomethylbenzimidazoles. Part I. Synthesis of 1- and 2-cyanomethylbenzimidazoles and some of their derivatives. *Pol. J. Pharmacol. Pharm.* **1974**, *26*, 639–646.
- [29] Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon,
 J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd,
 M. R. New colorimetric cytotoxicity assay for anticancer drug screening. *Natl. Cancer Inst.* **1990**, *82*, 1107–1112.
- [30] Vichai, V.; Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat. Protoc.* 2006, 1, 1112–1116.